FDA批准Eli Lilly的Interleukin-13抑制剂Ebglys 用于治疗中度至严重同位素皮炎。 FDA approves Eli Lilly's interleukin-13 inhibitor Ebglyss for treating moderate-to-severe atopic dermatitis.

艾利利利的Ebglyss (lebrikizumab) 已被FDA批准用于治疗中度至重度的亚托皮炎,适用于12岁及以上体重至少88磅且未对局部治疗有反应的患者. Eli Lilly's Ebglyss (lebrikizumab) has been approved by the FDA for treating moderate-to-severe atopic dermatitis in patients aged 12 and older who weigh at least 88 pounds and have not responded to topical therapies. 这种联素-13 抑制剂可减少炎症并改善皮肤症状. This interleukin-13 inhibitor reduces inflammation and improves skin symptoms. Ebglys每月注射一次,显示临床试验效果显著,许多病人皮肤明显改善。 Administered as a monthly injection, Ebglyss showed significant effectiveness in clinical trials, with many patients experiencing marked skin improvement.